Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy. - Gamerith, Gabriele; Auer, Thomas; Amann, Arno; Putzer, Daniel; Schenk, Bettina; Kircher, Brigitte; Hilbe, Wolfgang; Zwierzina, Heinz; Loeffler-Ragg, Judith (Cancer Biology & Therapy, 2014)